Halozyme Therapeutics (HALO) Operating Expenses (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Operating Expenses of $192.2 million for Q1 2026, up 55.84% year-over-year from $123.3 million in Q1 2025, and down 64.71% quarter-over-quarter from $544.7 million in Q4 2025.
Halozyme Therapeutics (HALO) Operating Expenses (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Operating Expenses for 17 consecutive years, with $192.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 55.84% year-over-year to $192.2 million; the TTM figure through Mar 2026 stood at $996.5 million (up 104.68% YoY), while the FY2025 annual figure was $927.6 million, up 99.98% from the prior year.
- Operating Expenses declined to $192.2 million in Q1 2026 per HALO's latest filing, from $544.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $544.7 million in Q4 2025 and bottomed at $41.6 million in Q1 2022.
- Historically, Operating Expenses has averaged $145.2 million across 5 years, with a median of $123.3 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Expenses fell 9.85% — and 2025, when it surged 344.59%.
- Halozyme Therapeutics' Operating Expenses stood at $107.0 million in 2022, then increased by 20.58% to $129.0 million in 2023, then decreased by 5.04% to $122.5 million in 2024, then surged by 344.59% to $544.7 million in 2025, then plunged by 64.71% to $192.2 million in 2026.
- Business Quant data shows HALO's Operating Expenses at $192.2 million in Q1 2026, $544.7 million in Q4 2025, and $136.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 193.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 193.35 Mn |
| Mar 31, 2026 | 192.19 Mn |
| Dec 31, 2025 | 544.66 Mn |
| Sep 30, 2025 | 136.34 Mn |
| Jun 30, 2025 | 123.28 Mn |
| Mar 31, 2025 | 123.33 Mn |
| Dec 31, 2024 | 122.51 Mn |
| Sep 30, 2024 | 126.89 Mn |
| Jun 30, 2024 | 114.12 Mn |
| Mar 31, 2024 | 100.34 Mn |
| Dec 31, 2023 | 129.00 Mn |
| Sep 30, 2023 | 127.75 Mn |
| Jun 30, 2023 | 126.58 Mn |
| Mar 31, 2023 | 108.34 Mn |
| Dec 31, 2022 | 106.99 Mn |
| Sep 30, 2022 | 125.68 Mn |
| Jun 30, 2022 | 118.31 Mn |
| Mar 31, 2022 | 41.61 Mn |
| Dec 31, 2021 | 45.47 Mn |
| Sep 30, 2021 | 40.24 Mn |